Skip to main content
. 2013 May 15;30(7):867–876. doi: 10.1007/s10585-013-9587-4

Fig. 2.

Fig. 2

BRAF mRNA expression and response to DTIC treatment. BRAF mRNA expression among patients experiencing a clinical benefit or progressive disease (PD) 3 months after commencement of DTIC chemotherapy. a BRAF expression in the total patient group, b data as presented in a, but limited to patients with tumors harboring wild-type BRAF, c similar analysis performed for tumors harboring BRAF V600 mutations. Asterisks denote significance levels: *p ≤ 0.05, **p ≤ 0.005